New hope for frail leukemia patients: gentler combo targets genetic flaw
NCT ID NCT07451912
Summary
This study is testing a three-drug combination (venetoclax pills plus two injectable drugs) to treat adults newly diagnosed with a specific genetic type of acute myeloid leukemia (AML) who are too frail for standard intensive chemotherapy. The main goals are to see how well this gentler treatment keeps the cancer from coming back and how many patients achieve a good initial response with manageable side effects. Participants will receive the treatment in cycles and be followed for two years to monitor their health and check for cancer recurrence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.